Recently, Professor Shi Yuanyuan, Chairman and General Manager of Shenzhen Cell Valley, along with Professor Wang Jianxun, Director and Chief Scientist; Dr. Fu Yuchen, Assistant to the Chairman; Dr. Zhao Lijun, Head of R&D; Sun Rui, Head of Marketing; and Guo Xiaohui from the Precision Medicine Department, visited Biosyngen (Guangzhou) Co., Ltd. for an exchange visit.They were warmly received by Professor Shen Hao, Global President and CEO of Biosyngen; Dr. Zhang Xi, Director and Chief Scientific Officer; Professor Jean-Paul Thiery, Chief Scientific Advisor and Chairman of the Scientific Committee (Academician of the French Academy of Sciences and the European Academy of Sciences); Dr. Huang Zhihong, R&D Director; and Dr. Liu Mingyu, Senior Scientist, among others.

Under the introduction of Professor Shen Hao and relevant staff from Biosyngen, the Shenzhen Cell Valley team visited core areas of Biosyngen, including the exhibition hall, quality control center, and international GMP production base. Through on-site visits and detailed explanations, the Shenzhen Cell Valley team gained a more in-depth and comprehensive understanding of Biosyngen's pipeline of genetically modified cell therapy products.

At the subsequent symposium, Professor Shi Yuanyuan stated that Shenzhen Cell Valley and Biosyngen maintain close ties and frequent exchanges. Previously, representatives from Biosyngen had visited the Shenzhen-Hong Kong Cell Valley, the international business headquarters of the Cell Valley Group. During that visit, both parties held in-depth discussions on innovative pipeline collaborations for cell therapies targeting solid tumors, including CAR-T, TCR-T, and TILs, and reached a preliminary consensus on cooperation.The purpose of this return visit to Biosyngen's  China base is to further deepen mutual understanding. Through on-site inspection, both sides aim to elevate their collaboration to a deeper level and broader scope, laying a solid foundation for the future implementation of joint projects.

Dr. Zhang Xi provided a detailed introduction to the development history and core business of Biosyngen to the Shenzhen Cell Valley team. Biosyngen was founded in 2016, with its headquarters in Singapore, and has established an internationally standardized GMP production base in Guangzhou, China. The company focuses on the global development of three major immunotherapy cell therapies: CAR-T, TCR-T, and TILs. Currently, eight pipeline products have successfully obtained IND approvals in both China and the United States. Its R&D pipeline covers various malignant tumor indications, including nasopharyngeal carcinoma, liver cancer, lung cancer, and gastrointestinal tumors, aiming to provide innovative and effective cell therapy solutions for cancer patients worldwide. In terms of scientific research collaboration and clinical resources, Biosyngen has deepened cooperation with top international institutions, gathering the world's leading research capabilities and abundant clinical resources. This provides a solid foundation for the development, clinical trials, and market promotion of its cell therapy products, while also injecting strong momentum into the company's continuous growth in the global cell therapy field.

This follow-up visit represents a significant opportunity for deepening bilateral cooperation. In the future, Shenzhen Cell Valley and Biosyngen will further enhance communication and collaboration, achieving deep integration in technical platform coordination, clinical resource sharing, promotion of local policies, and innovative drug registration applications. Together, they aim to create more internationally influential achievements in cell therapy for solid tumors.